Fig. 7
From: β-Glucan induced plasma B cells differentiation to enhance antitumor immune responses by Dectin-1
β-Glucan combined with anti-PD-1 therapy inhibits tumor growth in vivo. Experimental setup (n = 5–8/group) with mice being treated with WGP (1 mg) orally at day 7–20, or systemic anti-PD1 antibodies (20 µg) i.v. at day 7, 10, 13, 16, and 19 or combination. Mice were euthanized at day 21. (A) The tumor masses were measured with a caliper every other day once tumors were palpable, and tumor dimension volumes were calculated. Then tumor masses were photographed and weighed when the mice were euthanized. (B) Single cell suspensions from the tumor samples, DLN, or spleens, as indicated, were stained with fluorescein-labeled mAbs. The summarized data are shown. (C) The immunoglobulins of mouse serum samples were collected and assayed by LEGENDplex™ Mouse Immunoglobulin Isotyping Panel (6-plex). (D) qRT-PCR extracted the mRNA levels. A representative histogram from three independent experiments with similar results is shown. CON: black, PD1: red, PD1 + WGP: blue. (* P < 0.05, **P < 0.01, ***P < 0.001)